Welcome to our dedicated page for Xtl Biopharmaceu news (Ticker: XTLB), a resource for investors and traders seeking the latest updates and insights on Xtl Biopharmaceu stock.
XTL Biopharmaceuticals Ltd (XTLB) is a clinical-stage biopharmaceutical company advancing novel therapies for autoimmune diseases and hematological conditions. This page serves as the definitive source for official company announcements, research milestones, and partnership developments.
Access real-time updates on XTLB’s progress, including clinical trial results for its lead candidate hCDR1 targeting lupus and Sjogren’s syndrome, regulatory filings, and strategic collaborations. Investors will find press releases detailing trial designs, peer-reviewed data publications, and licensing agreements critical to evaluating the company’s trajectory.
Key content categories include pipeline advancements, scientific presentations, and manufacturing updates. All materials are sourced directly from XTL Biopharmaceuticals or verified industry publications to ensure accuracy. Bookmark this page for streamlined tracking of the company’s progress in addressing unmet medical needs through innovative biopharmaceutical solutions.
XTL Biopharmaceuticals (Nasdaq: XTLB) has appointed Noam Band as its new Chief Executive Officer, while Shlomo Shalev continues as Chairman of the Board of Directors. Band brings significant experience from his previous roles, including serving as CEO and Chairman of Gix Internet and CEO of Dotomi.
Band holds an MBA and B.A. in Economics from The Hebrew University of Jerusalem. His background includes strategic business development, market expansion, and operational leadership positions. XTL currently operates through its wholly-owned subsidiary, The Social Proxy , a web data AI company developing an ethical proxy data extraction platform. The company also maintains a sublicensed IP portfolio for hCDR1 in Lupus treatment.
XTL Biopharmaceuticals (NASDAQ: XTLB) has completed the acquisition of THE SOCIAL PROXY , an AI web data company, expanding its IP portfolio. The transaction involved XTL acquiring all of Social Proxy's share capital in exchange for ADSs representing 44.6% of XTL's issued share capital and a $430,000 cash payment. Additionally, XTL completed a private placement of $1.5 million to support growth and financial needs.
Social Proxy will operate as a fully owned subsidiary of XTL, with its shareholders appointing two representatives to XTL's board of directors. This acquisition aligns with XTL's strategy to expand its asset portfolio in high-potential areas, particularly in the AI Web Data market. The move is expected to add significant value to XTL and its shareholders.
XTL Biopharmaceuticals announced a definitive agreement to acquire The Social Proxy, an AI web data company. The deal involves issuing shares equating to 44.6% of XTL's issued share capital and paying $430,000. The acquisition aims to enhance XTL's asset portfolio with high-potential assets. The Social Proxy will operate as a subsidiary, with its shareholders appointing two board members. The transaction includes a $1.5 million private placement approved by shareholders, subject to closing conditions. XTL aims to leverage The Social Proxy's advanced IP-based platform for AI and BI applications.
